373 related articles for article (PubMed ID: 23520471)
1. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.
Kreahling JM; Foroutan P; Reed D; Martinez G; Razabdouski T; Bui MM; Raghavan M; Letson D; Gillies RJ; Altiok S
PLoS One; 2013; 8(3):e57523. PubMed ID: 23520471
[TBL] [Abstract][Full Text] [Related]
2. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
[TBL] [Abstract][Full Text] [Related]
3. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
Hirai H; Arai T; Okada M; Nishibata T; Kobayashi M; Sakai N; Imagaki K; Ohtani J; Sakai T; Yoshizumi T; Mizuarai S; Iwasawa Y; Kotani H
Cancer Biol Ther; 2010 Apr; 9(7):514-22. PubMed ID: 20107315
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.
Van Linden AA; Baturin D; Ford JB; Fosmire SP; Gardner L; Korch C; Reigan P; Porter CC
Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103
[TBL] [Abstract][Full Text] [Related]
5. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Rajeshkumar NV; De Oliveira E; Ottenhof N; Watters J; Brooks D; Demuth T; Shumway SD; Mizuarai S; Hirai H; Maitra A; Hidalgo M
Clin Cancer Res; 2011 May; 17(9):2799-806. PubMed ID: 21389100
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
[TBL] [Abstract][Full Text] [Related]
7. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
[TBL] [Abstract][Full Text] [Related]
8. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
[TBL] [Abstract][Full Text] [Related]
9. The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.
Liang L; He Y; Wang H; Zhou H; Xiao L; Ye M; Kuang Y; Luo S; Zuo Y; Feng P; Yang C; Cao W; Liu T; Roy M; Xiao X; Liu J
Br J Haematol; 2020 Oct; 191(1):62-76. PubMed ID: 32314355
[TBL] [Abstract][Full Text] [Related]
10. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
Mizuarai S; Yamanaka K; Itadani H; Arai T; Nishibata T; Hirai H; Kotani H
Mol Cancer; 2009 Jun; 8():34. PubMed ID: 19500427
[TBL] [Abstract][Full Text] [Related]
11. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
Bridges KA; Hirai H; Buser CA; Brooks C; Liu H; Buchholz TA; Molkentine JM; Mason KA; Meyn RE
Clin Cancer Res; 2011 Sep; 17(17):5638-48. PubMed ID: 21799033
[TBL] [Abstract][Full Text] [Related]
12. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.
Indovina P; Marcelli E; Di Marzo D; Casini N; Forte IM; Giorgi F; Alfano L; Pentimalli F; Giordano A
Cancer Biol Ther; 2014 Apr; 15(4):380-8. PubMed ID: 24365782
[TBL] [Abstract][Full Text] [Related]
13. Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.
Li Y; Saini P; Sriraman A; Dobbelstein M
Oncotarget; 2015 Oct; 6(32):32339-52. PubMed ID: 26431163
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
[TBL] [Abstract][Full Text] [Related]
15. Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy.
Foroutan P; Kreahling JM; Morse DL; Grove O; Lloyd MC; Reed D; Raghavan M; Altiok S; Martinez GV; Gillies RJ
PLoS One; 2013; 8(12):e82875. PubMed ID: 24358232
[TBL] [Abstract][Full Text] [Related]
16. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
Saini P; Li Y; Dobbelstein M
Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828
[TBL] [Abstract][Full Text] [Related]
17. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest.
Francis AM; Alexander A; Liu Y; Vijayaraghavan S; Low KH; Yang D; Bui T; Somaiah N; Ravi V; Keyomarsi K; Hunt KK
Mol Cancer Ther; 2017 Sep; 16(9):1751-1764. PubMed ID: 28619757
[TBL] [Abstract][Full Text] [Related]
18. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
[TBL] [Abstract][Full Text] [Related]
20. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]